Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/17323
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAlexiou, G. A.en
dc.contributor.authorGoussia, A.en
dc.contributor.authorVoulgaris, S.en
dc.contributor.authorFotopoulos, A. D.en
dc.contributor.authorFotakopoulos, G.en
dc.contributor.authorNtoulia, A.en
dc.contributor.authorZikou, A.en
dc.contributor.authorTsekeris, P.en
dc.contributor.authorArgyropoulou, M. I.en
dc.contributor.authorKyritsis, A. P.en
dc.date.accessioned2015-11-24T18:38:21Z-
dc.date.available2015-11-24T18:38:21Z-
dc.identifier.issn0344-5704-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/17323-
dc.rightsDefault Licence-
dc.subjectglioblastomaen
dc.subjectmrp5en
dc.subjectki-67en
dc.subjectprognosisen
dc.subjectmultidrug-resistanceen
dc.subjecthuman gliomasen
dc.subjecthuman brainen
dc.subjectproteinen
dc.subjecttemozolomideen
dc.subjecttumorsen
dc.subjectgeneen
dc.subjectchemotherapyen
dc.subjectcellsen
dc.titlePrognostic significance of MRP5 immunohistochemical expression in glioblastomaen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primaryDOI 10.1007/s00280-012-1832-z-
heal.identifier.secondary<Go to ISI>://000303418500032-
heal.identifier.secondaryhttp://link.springer.com/content/pdf/10.1007%2Fs00280-012-1832-z.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών και Τεχνολογιών. Τμήμα Βιολογικών Εφαρμογών και Τεχνολογιώνel
heal.publicationDate2012-
heal.abstractGlioblastoma multiforme (GBM) is the most frequent malignant primary brain tumor in adults, exhibiting poor survival. The efficacy of chemotherapy is often limited by the development of multidrug resistance by the tumor cells. In the current study, we investigated the prognostic significance of the multidrug resistance protein 5 (MRP5) in patients with GBM. We retrospectively studied 33 patients with GBM treated with a combination of surgery, postoperative radiotherapy and adjuvant temozolomide chemotherapy. MRP5 protein expression was determined immunohistochemically and correlated with other prognostic factors and survival. The immunohistochemical expression of MRP5 was observed in 0-45% of tumor cells. Patients with MRP5 index > 11% exhibited significantly worse survival compared to those with MRP5 index a parts per thousand currency sign11 (10.5 vs. 18 months, p = 0.0002). Patients with Ki-67 index lower than 30% had longer survival (15 vs. 11 months, p = 0.0084). Furthermore, patients with a gross total tumor excision had better survival (p = 0.016). No significant difference was observed between preoperative Karnofsky performance score, age, gender and survival. In multivariate analysis, MRP5 index and the extent of tumor resection were identified as factors with independent prognostic power. The present results imply that MRP5 index may hold a prognostic role in patients with GBM.en
heal.journalNameCancer Chemother Pharmacolen
heal.journalTypepeer reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Alexiou-2012-Prognostic significa.pdf223.91 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons